



File No. BIO/CT/23/000137

Dated 01-03-2024

To,

M/s. CuraTeQ Biologics Private Limited
Galaxy, Floors: 22-24, Plot No. 1, Survey No: 83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Ranga Reddy District,
Hyderabad-500032, Telangana, India.

Subject: Application for grant of permission to conduct Phase III clinical trial titled – " A Prospective, Randomized, Double Blind, Multicentre, Parallel Group Phase-III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of BP01(Bevacizumab) Versus EU approved Avastin® along with chemotherapy XELOX in metastatic colorectal cancer patients" as per protocol number ICS/CUR/2023-006, Version 1.0, dated 19 OCT 2023— regarding

Ref.: Your Application No BIO/CT04/FF/2023/40510 dated 14-11-2023

Sir,

With reference to your Application No. BIO/CT04/FF/2023/40510 dated 14-11-2023, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019. Further the Insurance certificate mentioning the protocol number and number of subjects should be submitted to CDSCO before initiating the trial.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVII) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified.
- (XVIII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.
- (XIX) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of two years from the date of its issue, unless extended by the Central Licencing Authority.
- (XX) The firm should submit Clinical study report (CSR) to this office after completion of trial.

Yours faithfully,

RAJEEV SINGH
(Dr. Rajeev Singh Raghuvanshi)
RAGHUVANSHI
Drugs Controller General (India)

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION,
ou=RAJEEV SINGH RAGHUVANSHI,
2.5.4.20=90c62f63234eafbe8a39774cde03c2769041015a06564e67
6EAF7A5701124A19013, DN: RAJEEV SINGH RAGHUVANSHI
2023.06.21 11:03:11 +05'30'

Annexure:**Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug	Bevacizumab 25 mg/mL concentrate for solution for infusion			
Therapeutic class	Antineoplastic agents			
Dosage form:	concentrate for solution for infusion			
Composition:	Name of Ingredient	Function	Quantity per vial	Quantity per ml
	Bevacizumab (rDNA origin) IH	Active ingredient	400mg	25mg
	Sodium Phosphate, monobasic monohydrate BP/USP	Buffer	92.8mg	5.8mg
	Sodium Phosphate, Dibasic anhydrous Ph.Eur/USP/JP	Buffer	19.2 mg	1.2mg
	α , α -Trehalose Dihydrate Ph.Eur/NF/JP	Stabilizer, osmolality adjustment agent	960 mg	60mg
	Polysorbate 20 Ph.Eur/JP/BP/NF	Stabilizer	6.4mg	0.4mg
	Water for Injection USP/Ph.Eur	Vehicle	q.s to 16 ml	q.s to 1ml
Indications:	Metastatic colorectal cancer			

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	Omega Hospital Chinnagadhili, Health City, Arilova, Hanumanthwaka, Visakhapatnam-530040	Institutional Ethics Committee, Omega Hospital Chinnagadhili, Health City, Arilova, Hanumanthwaka, Visakhapatnam-530040 <u>EC Reg. No.</u> ECR/1486/Inst/AP/2020	Dr. Bellala Ravi Shankar

2	Apex Wellness Hospital Survey No. 799, Plot No 187, Behind Prakash Petrol Pump, Govind Nagar, Nashik- 422009	Apex Wellness Ethics Committee Apex Wellness Hospital Survey No. 799, Plot No 187, Behind Prakash Petrol Pump, Govind Nagar, Nashik- 422009 EC reg no: ECR/1500/Inst/MH/2021	Dr Sandeep Vithoba Ishi
3	King George Hospital, Andhra Medical College, Visakhapatnam 530002	IEC King George Hospital King George Hospital, Andhra Medical College, Visakhapatnam 530002 EC reg no: ECR/197/Inst/KGH/2013/RR-20	Dr. Shilpa Kandipalli

